The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.

Provided herein is a composition comprising (a) nanoparticles comprising a poorly water soluble pharmaceutical agent and albumin, and (b) an edetate and citrate, wherein significant microbial growth is inhibited in the composition. Also provided is the composition of the invention for use in a method for the treatment of cancer in an individual. Further provided is a method of preserving a composition comprising nanoparticles comprising a poorly water soluble pharmaceutical agent and albumin against significant microbial growth comprising adding to the composition an edetate and citrate in an amount that is effective to inhibit significant microbial growth in the composition.

The present invention relates to compositions comprising particles, each of said particles comprising a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid [poly(I:C)], and at least one linear polyalkyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to use of said compositions as medicaments, in particular for the treatment of a cell growth disorder characterized by abnormal growth of human or animal cells, as well as to processes for the preparation of said compositions.

Disclosed herein are nanoparticles comprising an inorganic material having pores that can quickly absorb pharmaceutical moieties and then release such moieites in a controlled fashion for an extended period of time. The nanoparticles can be aggregated in order to form microaggregates that provide the same advantages of quick absorption and controlled release of pharmaceutical moieties. Quick absorption permits the preparation of drug-loaded nanoparticles and microaggregates essentially contemporaneously with the time of treatment, such as during a surgical process. Methods of preparing such nanoparticles and microaggregates are also provided, as are methods for administering a pharmaceutical moiety using the nanoparticles and microaggregates.

The present invention relates to a composition comprising magnetic nanoparticles for use in the treatment of a tissue volume comprising pathological cells in an individual, wherein a portion only of the tissue volume is occupied by the magnetic nanoparticles upon administration of the composition to the individual and the magnetic nanoparticles are excited by radiations

Variant ferritin polypeptides comprising a modified amino acid sequence of a wild-type ferritin (e.g. bacterioferritin), the modified sequence being in a dimeric subunit interface or the N-terminus of the polypeptide, wherein the variant may assemble into a ferritin nanocage when contacted with a nucleating agent (e.g. gold, iron, copper). Also claimed are fusion proteins comprising wild-type ferritin and a peptide selected from an antibody, antibody binding fragment, a fluorophore, a His tag and a nucleating agent binding peptide; a ferritin nanocage comprising the variant ferritin polypeptide or fusion protein.

This invention relates to a process for colloidosome-type microcapsules elaboration from solid particles microcapsules obtained by ionic gelation. In the process, an (O/W) type emulsion is initially generated stabilized with the solid particles microcapsules, and then the particles are fixed to the interface by adsorption of polyelectrolytes, cross-linking, heat treatment or fatty coating, generating the colloidosome with the water-insoluble phase encapsulated in the core and covered by the shell particles.

Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.

本发明公开了双重成像引导的光热治疗多功能纳米杂化物及制备方法，制备步骤为：(1)采用溶剂法制备硒化铋纳米板粉末：透明质酸掺杂聚吡咯包覆硒化铋纳米板：将硒化铋纳米板粉末和平均分子量为k13‑18的聚乙烯比咯烷酮溶于水中，加入吡咯，搅拌，转入冰浴，逐滴加入三氯化铁水溶液，加入透明质酸水溶液，反应；透析得聚合物溶液，离心，得到的沉淀物干燥,即得。本发明的杂化物物理稳定性好，且表现出好的水溶性，生物相容性，强的近红外吸收和良好的光热稳定性，可以用于CT，PA成像引导的光热治疗；具有良好的体内靶向性；制备工艺简单、反应条件温和、反应可控性强、低毒性、易规模化，所用原料易得、价格便宜。

本发明公开了种脂质纳米粒膜材料组合物，所述的膜材料组合物包括阳离子类脂、中性磷脂、胆固醇、吐温、聚乙二醇衍生物，所述的膜材料组合物比例为的摩尔比为（25‑35）:（40‑50）:（15‑25）：（1‑5）:（1‑5）。同时公开了由脂质纳米微粒膜材料组合物制备的脂质纳米粒的方法。本发明提供了种能够提高纳米微粒本身稳定性，从而促进药物在肿瘤组织的释放并且减小被降解的可能性的脂质纳米粒膜材料组合物。

本发明公开了种抑制bcl‑2的反义寡聚核酸的脂质纳米粒，属于生物技术领域。种抑制bcl‑2的反义寡聚核酸的脂质纳米粒是由膜材料包裹段反义寡聚核酸制成，所述的核酸序列为5’‑TCT CCC AGC GTG CGC CAT‑3’，或5’UCU CCC AGC GTG CGC CAU 3’。并公开了其制备方法。本发明中的纳米微粒，对肿瘤细胞的生长以及特定的靶基因有很好的阻断效果，特别是针对KB宫颈癌细胞具有很好的阻断效果。

本发明公开了乙二胺阳离子化白蛋白抗肿瘤纳米粒及其制备方法和用途。该白蛋白纳米制剂，优选以全反式维甲酸为抗肿瘤活性物质，以乙二胺阳离子化白蛋白为药物载体，加入分散剂、溶剂，采用白蛋白结合纳米微粒技术制备而成，平均粒径小于220nm。其制备方法为：将所述分散剂溶于水中配制成水相，所述全反式维甲酸溶于所述溶剂中配制成油相；将所述水相与所述油相混合高速剪切后均质，再经溶剂蒸发，冷冻干燥，制得所述白蛋白纳米制剂。本发明缩小白蛋白纳米粒径至纳米级水平，解决了溶解度问题，使人血白蛋白表面带正电荷，增加了与表面带负电荷的肿瘤细胞之间的吸附，加强其靶向性，降低不良反应，提高疗效，提高临床使用的适用性。

本发明属于生物医用材料应用技术领域，公开了种氨基化二氧化硅包裹的多孔普鲁士蓝纳米颗粒在pH响应型药物释放载体中的应用：将氨基化二氧化硅包裹的多孔普鲁士蓝纳米颗粒分散于药物溶液中，静置，离心、干燥后得到载药的氨基化二氧化硅包裹的多孔普鲁士蓝纳米颗粒，其在酸性条件下更易释放药物。该纳米颗粒的制备方法为：1）将铁氰化钾溶于盐酸中，在50‑100℃下反应15‑20小时，离心、洗涤、烘干，得普鲁士蓝纳米颗粒；2）将普鲁士蓝纳米颗粒和PVP溶于盐酸，在100‑140℃下反应4‑10小时，离心、洗涤、烘干，得多孔普鲁士蓝纳米颗粒；3）将CTAB和多孔普鲁士蓝纳米颗粒加入异丙醇中，再依次滴加氨水、超纯水、TEOS、APTES，滴完后，搅拌5‑10小时，离心、洗涤、烘干。

The present invention generally relates to particles, including nanoparticles, for example, for drug delivery or other applications. Certain aspects of the present invention are generally directed to particles, such as nanoparticles, comprising an inner portion and a coating. The inner portion may contain insulin or other therapeutic molecules for delivery to a living organism. In some cases, the molecules may be electrostatically complexed with an oppositely-charged peptide, such as an oligoarginine, or other species. The therapeutic molecules may also be water soluble. In some cases, the peptide may be conjugated to a hydrophobic portion, such as cholesterol, lauric acid, or a fatty acid chain. This hydrophobic modification may facilitate complex formation with the therapeutic molecule and the stability of the resulting complex. The complex typically is surrounded by a coating, which may protect the complex. For example, the coating may include polymers such as poly(glutamic acid) and poly(ethylene glycol). In some cases, the coated complex may also facilitate transport across cells, e.g., within the gastrointestinal tract. Other aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

本发明提供种荷载化疗药物的pH敏感的靶向纳米粒制剂及其制备方法。所述纳米粒采用叶酸修饰明胶使其等电点与肿瘤部位pH值接近，并使其与在正常生理环境下带相反电荷的材料通过静电结合组成纳米粒，同时包裹药物制成载药纳米制剂，当到达肿瘤组织后，弱酸性的微环境使明胶发生电荷反转，与内核材料由静电结合变为静电排斥，纳米粒分解，药物释放。从而实现pH敏感药物释放。再结合叶酸的靶向作用，实现抗肿瘤药物靶向性给药，实现高效低毒的给药方式。

本发明属于生物医用材料领域，具体公开了种氨基化二氧化硅包裹的多孔普鲁士蓝纳米颗粒及其制备方法和作为药物释放载体的应用，该纳米颗粒的制备方法为：1）将铁氰化钾溶于盐酸溶液中，在50‑100℃下反应15‑20小时，离心、洗涤、烘干，得普鲁士蓝纳米颗粒；2）将普鲁士蓝纳米颗粒和PVP溶于盐酸，在100‑140℃下反应4‑10小时，离心、洗涤、烘干，得多孔普鲁士蓝纳米颗粒；3）将CTAB和多孔普鲁士蓝纳米颗粒溶于异丙醇中，边搅拌边依次滴加氨水、超纯水、TEOS、APTES，滴加完后，搅拌5‑10小时，离心、洗涤、烘干，得氨基化二氧化硅包裹的多孔普鲁士蓝纳米颗粒。本发明的另目的在于将该氨基化二氧化硅包裹的多孔普鲁士蓝纳米颗粒作为药物的释放载体应用于临床抗癌治疗。

Pharmaceutical composition containing poly(bile) acid (PBA) polymers for oral delivery of agent(s) show enhanced uptake by the pancreas, liver, and colon. These nanoparticles show significant retention in the pancreas and colon and are therefore useful for selective delivery. The examples demonstrate efficacy of oral administration of insulin to treat diabetes, and oral induction of tolerance by administration of insulin or ovalbumin in combination with rapamycin. Diabetic animals treated with the insulin or insulin with rapamycin showed normalization of blood glucose levels.

A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from Quillaja Saponaria Molina (QuilQ) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a Quil A micelle and by an hydrophilic ester bond between a sterol OH− and COOH− or aldehyde groups in the QuilA micelle. It also relates to a composition comprising the nanoparticles, and the use thereof as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.

An active agent delivery system comprising a nanofiber web and an active agent carried by the nanofiber web.

Described herein are methods, formulations and kits for treating a patient with cancer with anti-VEGF antibodies and albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes. In another aspect, provided herein are methods for enhancing the efficacy of albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes. In another aspect, provided herein are methods for enhancing the therapeutic outcome in a patient suffering from a cancer expressing soluble VEGF which patient is selected to be treated with nanoparticles comprising albumin-bound paclitaxel and anti-VEGF antibodies wherein said antibodies of the nanoparticles are integrated onto and/or into said nanoparticles which method comprises treating said patient with a subtherapeutic amount of said anti-VEGF antibody prior to any subsequent treatment with the nanoparticles.

Abstract Compositions with improved particle transport in mucus are provided. The compositions include modifying the surface coatings of particles including pharmaceutical agents that have a low aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications.

The present invention relates to a pharmaceutical composition containing hyaluronic acid nanoparticles for preventing or treating an inflammatory disease and a metabolic disease and, more specifically, to a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease, the composition containing hyaluronic acid nanoparticles formed by allowing hyaluronic acid and 5β-cholanic acid or polycaprolactone to be bound to a hydrophobic moiety of the hyaluronic acid through self-assembly in an aqueous solution state. The pharmaceutical composition containing hyaluronic acid nanoparticles for preventing or treating an inflammatory disease or a metabolic disease according to the present invention has effects of reducing the body weight, decreasing the food intake, reducing the blood glucose as a result of glucose tolerance test (GTT), lowering the insulin resistance, reducing inflammation-inducing factors (NF-κB, IL-1β, CD44, TNF-α, NLRP3 inflammasome, and the like), and reducing the tissue infiltration of macrophages, alleviating arthritic symptoms, and reducing the prevalence rate thereof, and thus the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease.

The disclosure provides methods of treating immunological conditions, e.g., allergy, by administration of berberine nanoparticles.

Formulations containing pH-sensitive nanoparticles for the enteric delivery of therapeutic agents are provided. The nanoparticles include a pH-sensitive polymer that protects the therapeutic agent against degradation in the stomach and allows it to be released in the small intestine or colon. The nanoparticle formulation is particularly effective at protecting sensitive biotherapeutic agents from degradation when administered orally, and makes it possible to avoid administration of such agents by injection. Also provided are methods for producing the formulations, as well as methods of treating diseases employing the formulations.

Resumen de: WO2018071572A1

This disclosure relates to compositions and methods for editing or altering target nucleotide sequences based on nanoparticle delivery vehicles. The compositions and methods can be applied to influence the functional expression of target gene products encoded by DNA and/or RNA. In some embodiments, the altered gene sequences are useful to normalize and regulate the function of target cells.